Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Single-ascending Dose-escalation Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Anti-alpha2-antiplasmin (α2AP) Monoclonal Antibody TS23 in Healthy Human Volunteers

NCT03001544 is registered in ClinicalTrials.gov with Translational Sciences, Inc. as lead sponsor.

NCT NCT03001544
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03001544 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Single-ascending Dose-escalation Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Anti-alpha2-antiplasmin (α2AP) Monoclonal Antibody TS23 in Healthy Human Volunteers
Lead sponsor
Translational Sciences, Inc.
Phase
Phase 1
Overall status
Unknown status
Start date
July 31, 2015
Completion date
June 30, 2017
Enrollment
24 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cerebral ischemia, myocardial infarction, pulmonary embolism, thrombosis, venous thrombosis